

Serial No.: 09/807,657  
Group Art Unit No.: 1648

**REMARKS**

Applicants request that the Examiner consider the attached Supplemental IDS and examine the claims in view of the added references.

Claims 1-31, 38, 43, 47, 54, 57, 63-70, 72, 83, 87, 94, 98, 105, 117-119, 126, 128, and 130 have been cancelled. Claims 32-37, 39-42, 44-46, 48-53, 71, 73-82, 84-86, 88-93, 95-97, 99-104, 106-116, 120-125, 127, 129-131, and 133-141 are pending. Claims 32-37, 39-42, 44-46, 48-53, 71, 73-82, 84-86, 88-93, 95-97, 99-104, 106-114, 116, 120-124, 127, 129-131, and 133-137 have been amended.

Claim 32 has been amended to reflect the fact that the immunostimulant is selected from the group consisting of monophosphoryl lipid A, derivatives thereof, an immunostimulatory nucleotide, and an immunostimulatory cytokine. Basis for the amendment to this claim (as well as Claim 42) can be found in the specification, page 1, lines 4-5 and page 5, line 30. This amendment puts Claim 32 and claims depending therefrom in condition for allowance. Claims 33-37, 39-41, 44-46, 48-53, 71, 73-82, 84-86, 88-93, 95-97, 99-104, 106-114, 116, 120-124, 127, 129-131, and 133-137 have been amended to more particularly point out and distinctly claim what Applicants consider their invention to be. No new matter has been added nor has the scope of the claims been broadened by these amendments. Inasmuch as the remaining claims were found to be allowable except for the objection to Claim 32, Applicants respectfully request that a Notice of Allowance be granted for 32-37, 39-42, 44-46, 48-53, 55, 56, 58-62, 71, 73-82, 84-86, 88-93, 95-97, 99-104, 106-116, 120-125, 127, 129-131, and 133-141.

Respectfully submitted,



Reid S. Willis  
Attorney for Applicant  
Registration No. 39,429

GLAXOSMITHKLINE  
Corporate Intellectual Property - UW2220  
P.O. Box 1539  
King of Prussia, PA 19406-0939  
Phone (610) 270-7481  
Facsimile (610) 270-5090  
N:\Reid\patapps\B45158X\NRCE amendment.doc